A third-generation IMiD for MM

Cavo, Michèle

doi:10.1182/blood-2011-07-364315

Cited by 11 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lenalidomide was also shown to inhibit chronic lymphocytic leukemia (CLL) cell proliferation via cereblon-p21-dependent manner [18]. More recently, pomalidomide, which has greater in vitro activity than thalidomide or lenalidomide [9], received approval for the treatment of relapsed and refractory MM.…”

Section: Crbn As a Binding Target Of Imidsmentioning

confidence: 98%

Cereblon in health and disease

Kim

Nyamaa

et al. 2016

Pflugers Arch - Eur J Physiol

View full text Add to dashboard Cite

Cereblon (CRBN) is a substrate receptor of the E3 ubiquitin ligase complex that has been linked to autosomal recessive non-syndromic mental retardation. Several key findings suggest diverse roles of CRBN, including its regulation of the large-conductance calcium- and voltage-activated potassium (BKCa) channels, regulation of thalidomide-binding proteins, and mediation of lenalidomide treatment in multiple myeloma. Recent studies also indicate that CRBN is involved in energy metabolism and negatively regulates AMP-activated protein kinase signaling. Mice with genetic depletion of CRBN are resistant to various stress conditions including a high-fat diet, endoplasmic reticulum stress, ischemia/reperfusion injury, and alcohol-related liver damage. In this review, we discuss the various roles of CRBN in human health and disease and suggest avenues for further research to enhance our basic knowledge and clinical application of CRBN.

show abstract

Section: Crbn As a Binding Target Of Imidsmentioning

confidence: 98%

Cereblon in health and disease

Kim

Nyamaa

et al. 2016

Pflugers Arch - Eur J Physiol

View full text Add to dashboard Cite

show abstract

“…CRBN was also reported as a primary target protein of immunomodulatory drugs, including thalidomide [3] and its derivatives lenalidomide and pomalidomide [10]. Thalidomide was originally prescribed as a sedative for pregnant women to prevent morning sickness and found to be a teratogen, but thalidomide and its derivatives are now widely used in the treatment of hematologic malignancies such as multiple myeloma [11,12] and 5q deletion-associated myelodysplastic syndrome [13]. Thalidomide binds CRBN and inhibits CRL4 CRBN activity, leading to a teratogenic effect on fetal development [3].…”

Section: Introductionmentioning

confidence: 99%

Ubiquitin-dependent proteasomal degradation of AMPK gamma subunit by Cereblon inhibits AMPK activity

Yang

Jeon

Nguyen

et al. 2020

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…With the recent advances in supportive care, autologous HSCT has been extended to include older patients with MM and those with comorbid medical conditions such as renal failure (RF) [37,38]. Nevertheless, autologous HSCT and novel therapies are complementary to each other in the management of patients with MM [37,40].…”

Section: Introductionmentioning

confidence: 99%

Introductory Chapter: Multiple Myeloma in the Era of Novel Therapeutics

Al-Anazi¹

2019

Update on Multiple Myeloma

View full text Add to dashboard Cite

A third-generation IMiD for MM

Cited by 11 publications

References 9 publications

Cereblon in health and disease

Cereblon in health and disease

Ubiquitin-dependent proteasomal degradation of AMPK gamma subunit by Cereblon inhibits AMPK activity

Introductory Chapter: Multiple Myeloma in the Era of Novel Therapeutics

Contact Info

Product

Resources

About